Atlas Trials

A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP

Clinical trial NCT07702851 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07702851
Sponsor
Yonsei University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B-cell Lymphoma
Start date
2026-09-01
Primary completion
2030-08-31
Enrollment
47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.